439 related articles for article (PubMed ID: 30828801)
21. Uncoupling protein 2 reprograms the tumor microenvironment to support the anti-tumor immune cycle.
Cheng WC; Tsui YC; Ragusa S; Koelzer VH; Mina M; Franco F; Läubli H; Tschumi B; Speiser D; Romero P; Zippelius A; Petrova TV; Mertz K; Ciriello G; Ho PC
Nat Immunol; 2019 Feb; 20(2):206-217. PubMed ID: 30664764
[TBL] [Abstract][Full Text] [Related]
22. Myeloid-derived Suppressor Cells Elimination by 5-Fluorouracil Increased Dendritic Cell-based Vaccine Function and Improved Immunity in Tumor Mice.
Khosravianfar N; Hadjati J; Namdar A; Boghozian R; Hafezi M; Ashourpour M; Kheshtchin N; Banitalebi M; Mirzaei R; Razavi SA
Iran J Allergy Asthma Immunol; 2018 Feb; 17(1):47-55. PubMed ID: 29512369
[TBL] [Abstract][Full Text] [Related]
23. Tumour-derived small extracellular vesicles suppress CD8+ T cell immune function by inhibiting SLC6A8-mediated creatine import in NPM1-mutated acute myeloid leukaemia.
Peng M; Ren J; Jing Y; Jiang X; Xiao Q; Huang J; Tao Y; Lei L; Wang X; Yang Z; Yang Z; Zhan Q; Lin C; Jin G; Zhang X; Zhang L
J Extracell Vesicles; 2021 Nov; 10(13):e12168. PubMed ID: 34807526
[TBL] [Abstract][Full Text] [Related]
24. Irradiation Enhances Abscopal Anti-tumor Effects of Antigen-Specific Immunotherapy through Regulating Tumor Microenvironment.
Chang MC; Chen YL; Lin HW; Chiang YC; Chang CF; Hsieh SF; Chen CA; Sun WZ; Cheng WF
Mol Ther; 2018 Feb; 26(2):404-419. PubMed ID: 29248428
[TBL] [Abstract][Full Text] [Related]
25. Updates on DNA methylation modifiers in acute myeloid leukemia.
Contieri B; Duarte BKL; Lazarini M
Ann Hematol; 2020 Apr; 99(4):693-701. PubMed ID: 32025842
[TBL] [Abstract][Full Text] [Related]
26. Dramatic efficacy improvement of a DC-based vaccine against AML by CD25 T cell depletion allowing the induction of a long-lasting T cell response.
Delluc S; Hachem P; Rusakiewicz S; Gaston A; Marchiol-Fournigault C; Tourneur L; Babchia N; Fradelizi D; Regnault A; Sang KH; Chiocchia G; Buzyn A
Cancer Immunol Immunother; 2009 Oct; 58(10):1669-77. PubMed ID: 19225777
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic therapy with chidamide alone or combined with 5‑azacitidine exerts antitumour effects on acute myeloid leukaemia cells
Li Z; Zhang J; Zhou M; Li JL; Qiu QC; Fu JH; Xue SL; Qiu HY
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35103292
[TBL] [Abstract][Full Text] [Related]
28. Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.
Yan J; Tingey C; Lyde R; Gorham TC; Choo DK; Muthumani A; Myles D; Weiner LP; Kraynyak KA; Reuschel EL; Finkel TH; Kim JJ; Sardesai NY; Ugen KE; Muthumani K; Weiner DB
Cancer Gene Ther; 2014 Dec; 21(12):507-17. PubMed ID: 25394503
[TBL] [Abstract][Full Text] [Related]
29. Retroviral transduction of acute myeloid leukaemia-derived dendritic cells with OX40 ligand augments their antigen presenting activity.
Yanagita S; Hori T; Matsubara Y; Ishikawa T; Uchiyama T
Br J Haematol; 2004 Feb; 124(4):454-62. PubMed ID: 14984494
[TBL] [Abstract][Full Text] [Related]
30. Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model.
Stroopinsky D; Liegel J; Bhasin M; Cheloni G; Thomas B; Bhasin S; Panchal R; Ghiasuddin H; Rahimian M; Nahas M; Orr S; Capelletti M; Torres D; Tacettin C; Weinstock M; Bisharat L; Morin A; Mahoney KM; Ebert B; Stone R; Kufe D; Freeman GJ; Rosenblatt J; Avigan D
Haematologica; 2021 May; 106(5):1330-1342. PubMed ID: 33538148
[TBL] [Abstract][Full Text] [Related]
31. Immune checkpoint Ab enhances the antigen-specific anti-tumor effects by modulating both dendritic cells and regulatory T lymphocytes.
Sun NY; Chen YL; Lin HW; Chiang YC; Chang CF; Tai YJ; Chen CA; Sun WZ; Chien CL; Cheng WF
Cancer Lett; 2019 Mar; 444():20-34. PubMed ID: 30543813
[TBL] [Abstract][Full Text] [Related]
32. Digging deep into "dirty" drugs - modulation of the methylation machinery.
Pleyer L; Greil R
Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
[TBL] [Abstract][Full Text] [Related]
33. A skewed distribution and increased PD-1+Vβ+CD4+/CD8+ T cells in patients with acute myeloid leukemia.
Huang J; Tan J; Chen Y; Huang S; Xu L; Zhang Y; Lu Y; Yu Z; Chen S; Li Y
J Leukoc Biol; 2019 Sep; 106(3):725-732. PubMed ID: 31136687
[TBL] [Abstract][Full Text] [Related]
34. Fusion hybrids of dendritic cells and autologous myeloid blasts as a potential cellular vaccine for acute myeloid leukaemia.
Klammer M; Waterfall M; Samuel K; Turner ML; Roddie PH
Br J Haematol; 2005 May; 129(3):340-9. PubMed ID: 15842657
[TBL] [Abstract][Full Text] [Related]
35. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
36. Gene transfer to primary acute myeloid leukaemia blasts and myeloid leukaemia cell lines.
Roddie PH; Paterson T; Turner ML
Cytokines Cell Mol Ther; 2000 Sep; 6(3):127-34. PubMed ID: 11140881
[TBL] [Abstract][Full Text] [Related]
37. Characteristics of NK cells from leukemic microenvironment in MLL-AF9 induced acute myeloid leukemia.
Yang F; Wang R; Feng W; Chen C; Yang X; Wang L; Hu Y; Ren Q; Zheng G
Mol Immunol; 2018 Jan; 93():68-78. PubMed ID: 29154208
[TBL] [Abstract][Full Text] [Related]
38. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8
Enamorado M; Iborra S; Priego E; Cueto FJ; Quintana JA; Martínez-Cano S; Mejías-Pérez E; Esteban M; Melero I; Hidalgo A; Sancho D
Nat Commun; 2017 Jul; 8():16073. PubMed ID: 28714465
[TBL] [Abstract][Full Text] [Related]
39. Elevated fetal haemoglobin is a predictor of better outcome in MDS/AML patients receiving 5-aza-2'-deoxycytidine (Decitabine).
Lübbert M; Ihorst G; Sander PN; Bogatyreva L; Becker H; Wijermans PW; Suciu S; Bissé E; Claus R
Br J Haematol; 2017 Feb; 176(4):609-617. PubMed ID: 27905102
[TBL] [Abstract][Full Text] [Related]
40. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Daver N; Boddu P; Garcia-Manero G; Yadav SS; Sharma P; Allison J; Kantarjian H
Leukemia; 2018 May; 32(5):1094-1105. PubMed ID: 29487386
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
